Ranjit Manchanda is a Clinical Senior Lecturer at Barts Cancer Institute, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital, London, UK
Ranjit’s research interests are focused around population based germline testing and precision medicine approaches for risk prediction, stratification, as well as targeted screening & cancer prevention. He has a keen interest in health service resource and health economic research issues. He is the research lead and Principal Investigator on the PROMISE Pilot study (Feasibility of population based risk prediction and stratification for targeting ovarian cancer screening and prevention), GCaPPS trial (Randomised Trial on population based BRCA testing in the UK Jewish population), PROTECTOR trial (Trial evaluating salpingectomy for ovarian cancer prevention in high-risk women) and SIGNPOST study (Study evaluating outcomes of germline panel and somatic tumour testing in ovarian cancer patients). He has published and lectured widely on areas of his research interest. He chairs the Barts Health Gynae-oncology trials group. He is a member of the UK NCRI Ovarian Cancer Surgical Sub group, European Network of Prevention in Gynaecological Oncology (ENPIGO), and a number of a number of advisory bodies and oversight committees. He has served as the President of the European Network of Young Gynaecological Oncologists (ENYGO) as well as a member of the European Society of Gynaecological Oncology (ESGO) Council from 2011 to 2013.
His clinical interests include management of familial gynaecological cancer, ultra-radical debulking surgery for ovarian cancer & advanced complex laparoscopic surgery for gynaecological cancers. He leads the Familial Gynaecological cancer service at Barts Health NHS Trust, London.